The state of SOHO: a year of growth and opportunity
When SOHO was founded in 2012, we envisioned a society that would provide education, insight, connection, and meaningful opportunities for collaboration among clinicians
When SOHO was founded in 2012, we envisioned a society that would provide education, insight, connection, and meaningful opportunities for collaboration among clinicians
Patients with low-risk myelodysplastic syndromes (LR-MDS) with bone marrow fibrosis (MF) display a cytokine pattern characterized by elevated interleukin 1β (IL-1β) and reduced
Volume 4 of the SOHO Insider Daily Newspaper from the SOHO 2026 Annual Meeting features an interview on modern acute lymphoblastic leukemia
Volume 3 of the SOHO Insider Daily Newspaper from the SOHO 2026 Annual Meeting features a guest editorial on myelodysplastic syndromes by incoming
SOHO 2026 Friday plenary features NIH scientist and aplastic anemia expert Dr. Neal S. Young. The plenary will take place at 1:47 pm
Dr. Alderuccio highlighted data from the ECHELON-3 trial supporting FDA-approved brentuximab vedotin with lenalidomide and rituximab as an option that can be provided
My day-to-day is pretty much operational and involves a little bit of everything. When I first started with SOHO 15 years ago, we
Dr. O’Brien, a founding member of the society, has contributed far beyond her scientific expertise. Known for her dedication and commitment to the
Volume 2 of the SOHO Insider Daily Newspaper from the SOHO 2026 Annual Meeting features an editorial on CML outcomes in low-
Oral abstract ALL-584 takes top honors in SOHO 2026 abstract awards.